Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25755006 | 0.96 | SLC6A2 (0.33) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25755005 | 0.95 | SLC6A2 (0.33) | KDM4EALDH1A1POLBHTR4SLC6A2 | |
| SCHEMBL25755008 | 0.90 | HTR4 (0.31) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25755012 | 0.90 | SLC6A2 (0.33) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25755015 | 0.84 | HTR4 (0.33) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25755004 | 0.84 | SLC6A2 (0.33) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25754771 | 0.83 | HDAC1 (0.37) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25755032 | 0.83 | HTR4 (0.30) | HTR4 | |
| SCHEMBL25755007 | 0.80 | SLC6A2 (0.32) | HTR4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25754773 | 0.79 | SLC6A2 (0.36) | HTR4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM4E 2658/4885ALDH1A1 2539/4885POLB 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.